ATE168415T1 - Wasserlösliche peptidanaloguen mit bindungstellen - Google Patents

Wasserlösliche peptidanaloguen mit bindungstellen

Info

Publication number
ATE168415T1
ATE168415T1 AT91909574T AT91909574T ATE168415T1 AT E168415 T1 ATE168415 T1 AT E168415T1 AT 91909574 T AT91909574 T AT 91909574T AT 91909574 T AT91909574 T AT 91909574T AT E168415 T1 ATE168415 T1 AT E168415T1
Authority
AT
Austria
Prior art keywords
complement
water soluble
binding sites
peptide analogues
directed
Prior art date
Application number
AT91909574T
Other languages
English (en)
Inventor
Thomas Hebell
Douglas T Fearon
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE168415T1 publication Critical patent/ATE168415T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Led Device Packages (AREA)
  • Led Devices (AREA)
AT91909574T 1990-04-25 1991-04-25 Wasserlösliche peptidanaloguen mit bindungstellen ATE168415T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51329990A 1990-04-25 1990-04-25

Publications (1)

Publication Number Publication Date
ATE168415T1 true ATE168415T1 (de) 1998-08-15

Family

ID=24042678

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91909574T ATE168415T1 (de) 1990-04-25 1991-04-25 Wasserlösliche peptidanaloguen mit bindungstellen

Country Status (8)

Country Link
US (1) US6458360B1 (de)
EP (1) EP0528926B1 (de)
JP (1) JPH05507197A (de)
AT (1) ATE168415T1 (de)
AU (1) AU7876691A (de)
CA (1) CA2081207A1 (de)
DE (1) DE69129803D1 (de)
WO (1) WO1991016437A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
GB9424631D0 (en) 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
SK288144B6 (sk) 1996-02-09 2013-12-02 Amgen, Inc. Pharmaceutical composition and its use for treating inflammatory diseases
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6820011B2 (en) * 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
JP2004529945A (ja) * 2001-05-17 2004-09-30 ラ ホヤ ファーマシューティカル カンパニー Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
AU2003298650B2 (en) 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
WO2005069726A2 (en) 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US9493538B2 (en) * 2004-05-28 2016-11-15 University Of Massachusetts Snares for pathogenic or infectious agents and uses related thereto
WO2006128006A1 (en) * 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US7807409B2 (en) 2005-10-21 2010-10-05 Roche Palo Alto Llc Method for the recombinant expression of a polypeptide
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CA2666843C (en) * 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
US8937046B2 (en) * 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
AU2011301996A1 (en) 2010-09-15 2013-03-21 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
WO2012058479A2 (en) 2010-10-27 2012-05-03 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
EP2938634A2 (de) * 2012-12-28 2015-11-04 AbbVie Inc. Spezifische doppeltbindende proteine mit einer rezeptorsequenz
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CA2944605C (en) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
EP3194449A1 (de) 2014-07-24 2017-07-26 Xencor, Inc. Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
NZ191320A (en) 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
EP0028489B1 (de) 1979-11-05 1983-10-05 Beecham Group Plc Enzym-Derivate und ihre Herstellung
US4642284A (en) 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US4672044A (en) 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
EP0281604B1 (de) 1986-09-02 1993-03-31 Enzon Labs Inc. Bindungsmoleküle mit einzelpolypeptidkette
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE68926888T2 (de) * 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
PT89484B (pt) 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
US4937183A (en) 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
AU4341189A (en) 1988-10-03 1990-05-01 Scripps Clinic And Research Foundation The receptor binding region of ebvgp350
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
AT402153B (de) 1989-06-26 1997-02-25 Immuno Ag Protein-s-hältige pharmazeutische präparation
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins

Also Published As

Publication number Publication date
AU7876691A (en) 1991-11-11
JPH05507197A (ja) 1993-10-21
EP0528926B1 (de) 1998-07-15
EP0528926A1 (de) 1993-03-03
DE69129803D1 (de) 1998-08-20
CA2081207A1 (en) 1991-10-26
WO1991016437A1 (en) 1991-10-31
US6458360B1 (en) 2002-10-01

Similar Documents

Publication Publication Date Title
ATE168415T1 (de) Wasserlösliche peptidanaloguen mit bindungstellen
ATE194382T1 (de) Neuartige polypeptide zur unterstützung der zellfixierung
DK1642973T3 (da) Terapeutisk anvendelser af BR43X2-oplöselige receptorer
DE68926303D1 (de) Peptide und antikörper, die die integrin-ligandbindung inhibieren
DK161015C (da) Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop
IL96043A0 (en) Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
DE69129865D1 (de) Osteogene peptide
DE69132275D1 (de) Beta-type ähnlicher transformierender wachstumfaktor
ATE295736T1 (de) Verwendung von interleukin-15
KR950704489A (ko) 인터페론 타우 조성물 및 사용방법(interferon tau compositions and methods of use)
ES550943A0 (es) Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana.
FI961044A0 (fi) Kininogeeni-inhibiittorit
ATE144535T1 (de) Plättchen blockierende peptide
DK0863155T3 (da) Suppression af T-celle-proliferation under anvendelse af peptidfragmenter af myelin basisk protein
DK611386A (da) Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden
DE69715181D1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
DE69925116D1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
DK0404967T3 (da) Rekombinante C-terminal-alfa-amiderende enzym af human skjoldbruskkirtel-oprindelse
Benhamini et al. Immunochemical studies with synthetic peptides related to collagen
DE69032096D1 (de) Antikörper gegen das carboxy-terminale Peptid des Somatotropin-Bindungsproteins der Ratte
JPS6460388A (en) Gene coding linked material of protein a-like substance fc bond region, recombinant plasmid containing said gene and transformant produced by using said recombinant plasmid
KR970061914A (ko) 생물학적으로 유용한 펩타이드
EA199900432A1 (ru) Ice-ингибирующие пептиды

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties